Moleculin Biotech (Moleculin Biotech) Change In Inventory : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Moleculin Biotech Change In Inventory?

Moleculin Biotech's change in inventory for the quarter that ended in Dec. 2023 was $0.00 Mil. It means Moleculin Biotech's inventory stayed the same from Sep. 2023 to Dec. 2023 .

Moleculin Biotech's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Moleculin Biotech's inventory stayed the same from Dec. 2022 to Dec. 2023 .

Moleculin Biotech's Total Inventories for the quarter that ended in Dec. 2023 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Moleculin Biotech Change In Inventory Historical Data

The historical data trend for Moleculin Biotech's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moleculin Biotech Change In Inventory Chart

Moleculin Biotech Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Get a 7-Day Free Trial

Moleculin Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Moleculin Biotech Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Moleculin Biotech (NAS:MBRX) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Moleculin Biotech's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Moleculin Biotech's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Moleculin Biotech's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

Moleculin Biotech Change In Inventory Related Terms

Thank you for viewing the detailed overview of Moleculin Biotech's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Moleculin Biotech (Moleculin Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moleculin Biotech Inc (NAS:MBRX) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

MOLA:Germany

Address

5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007

Website

https://www.moleculin.com

Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member.

Executives

Jonathan P. Foster	officer: Exec. Vice President and CFO	2450 SOUTH SHORE BLVD., SUITE 402, LEAGUE CITY TX 77573
Walter V Klemp	director, 10 percent owner, officer: Chairman and Acting CEO	1415 WEST LOOP NORTH, HOUSTON TX 77055
Robert E. George	director	2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
Joy Yan	director	10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Elizabeth Cermak	director	1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Waldemar Priebe	10 percent owner	2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
John M Climaco	director	PO BOX 326, PARK CITY UT 84060
Jacqueline Northcut	director	2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
Donald H Picker	10 percent owner, officer: President and COO
Michael D Cannon	director	C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902
Louis Jr Ploth	officer: Chief Financial Officer	2408 TIMBERLOCH PLACE STE B1, WOODLANDS TX 77380